Research and Big Data Carl McKinley, Privacy and Compliance Officer, Regenstrief Institute Mitch Parker, CISO, Indiana University Health Stanley Crosley, Principal, Crosley Law Offices Titus Schleyer, Program Director, Regenstrief Institute

• What are your concerns about using AI in healthcare?
• How is AI already being used in healthcare?
• What do you want compliance to understand about AI?
• What is bias in AI and how does bias effect AI?

Break

Telehealth: The New Normal Nicholas Merker, Partner, Ice Miller

• How health care professionals are adapting away from the in-person visit and to telehealth from a business perspective
• What does telehealth compliance look like and how do professionals prepare for the inevitable withdrawal of OCR’s leniency enforcement period after COVID-19
• Billing compliance issues in a telehealth world

Break

Perspectives of Compliance Officers: How to Thrive as a Compliance Officer Jasmin French, Sr Mgr Ethics & Compliance, Cummins Inc. Steven Guymon, Corporate Ethics and Compliance Officer, Eli Lilly and Company Clarice McCauley, Assistant General Counsel, Ethics & Compliance, Roche Diagnostics Corporation Lisa Martin, VP, Chief Compliance Officer, Indiana University Health

• Identify tactics for collaboration with business leaders
• Assess organizational risk and remediation
• Drive professionalism and continuous improvement in the ethics and compliance program

Lunch Break

Pharmacy Compliance Christopher Dang, Attorney, Quarles

• Understanding the status of coronavirus-related pharmacy changes
• 340B Compliance Update and Hot Topics
• Pharmacy audit prep
• Controlled substances compliance

Break

OIG Mandated Six-Year Look Back Audits Chad Eckhardt, Partner and Chair - Healthcare Innovation Team, Frost Brown Todd LLC James Rose, Managing Director, SunHawk Consulting LLC

• Use of Statistical Sampling and Extrapolation
• Recent Updates and Perspectives
• Drivers of Efficient and Diligent Analysis

Break

Measuring the Effectiveness of a Compliance Program Using the DOJ Guidance Joseph Zielinski, Director of Legal Affairs, CarDon & Associates, Inc

• How to analyze the three "fundamental questions" that pursuant to Department of Justice guidance should be asked to determine the effectiveness of a compliance program
• How to apply and reference other compliance guidance to the Department of Justice’s three "fundamental questions"
• How to assess the effectiveness of a compliance program using the DOJ’s guidance, which specifically calls out various elements associated with a compliance program and what questions to ask to assess these elements (tool provided to assist in this assessment)